Evidence map›Paper›PMID 29636461›Full record

ArticleNature communications2018

Increased formate overflow is a hallmark of oxidative cancer.

Johannes Meiser, Anne Schuster, Matthias Pietzke, Johan Vande Voorde, Dimitris Athineos, Kristell Oizel, Guillermo Burgos-Barragan, Niek Wit, Sandeep Dhayade, Jennifer P Morton and 7 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 117 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Tracing the Diverse Paths of One-Carbon Metabolism in Cancer and Beyond.Cold Spring Harbor perspectives in medicine · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 3 countries.

Johannes MeiserCancer Research UK Beatson Institute, Glasgow, G61 1BD, UK.ORCID http://orcid.org/0000-0002-9093-6210
Anne SchusterDepartment of Oncology, NorLux Neuro-Oncology Laboratory, Luxembourg Institute of Health, L-1526, Luxembourg, Luxembourg.
Matthias PietzkeCancer Research UK Beatson Institute, Glasgow, G61 1BD, UK.
Johan Vande VoordeCancer Research UK Beatson Institute, Glasgow, G61 1BD, UK.
Dimitris AthineosCancer Research UK Beatson Institute, Glasgow, G61 1BD, UK.ORCID http://orcid.org/0000-0001-5298-7941
Kristell OizelCancer Research UK Beatson Institute, Glasgow, G61 1BD, UK.
Guillermo Burgos-BarraganMRC Laboratory of Molecular Biology, Cambridge, CB2 0QH, UK.
Niek WitMRC Laboratory of Molecular Biology, Cambridge, CB2 0QH, UK.
Sandeep DhayadeCancer Research UK Beatson Institute, Glasgow, G61 1BD, UK.
Jennifer P MortonCancer Research UK Beatson Institute, Glasgow, G61 1BD, UK.
Emmanuel DornierCancer Research UK Beatson Institute, Glasgow, G61 1BD, UK.ORCID http://orcid.org/0000-0002-3482-8637
David SumptonCancer Research UK Beatson Institute, Glasgow, G61 1BD, UK.
Gillian M MackayCancer Research UK Beatson Institute, Glasgow, G61 1BD, UK.
Karen BlythCancer Research UK Beatson Institute, Glasgow, G61 1BD, UK.ORCID http://orcid.org/0000-0002-9304-439X
Ketan J PatelMRC Laboratory of Molecular Biology, Cambridge, CB2 0QH, UK.
Simone P NiclouDepartment of Oncology, NorLux Neuro-Oncology Laboratory, Luxembourg Institute of Health, L-1526, Luxembourg, Luxembourg.ORCID http://orcid.org/0000-0002-3417-9534
Alexei VazquezCancer Research UK Beatson Institute, Glasgow, G61 1BD, UK. a.vazquez@beatson.gla.ac.uk.ORCID http://orcid.org/0000-0003-2764-3244
Cancer Research UK Scotland Institute · GBMRC Laboratory of Molecular Biology · GBLuxembourg Institute of Health · LU

Funding

Cancer Research UK 21140Medical Research Council MC_U105178811
6 · The paper itself

Abstract

Formate overflow coupled to mitochondrial oxidative metabolism\ has been observed in cancer cell lines, but whether that takes place in the tumor microenvironment is not known. Here we report the observation of serine catabolism to formate in normal murine tissues, with a relative rate correlating with serine levels and the tissue oxidative state. Yet, serine catabolism to formate is increased in the transformed tissue of in vivo models of intestinal adenomas and mammary carcinomas. The increased serine catabolism to formate is associated with increased serum formate levels. Finally, we show that inhibition of formate production by genetic interference reduces cancer cell invasion and this phenotype can be rescued by exogenous formate. We conclude that increased formate overflow is a hallmark of oxidative cancers and that high formate levels promote invasion via a yet unknown mechanism.

Indexed as

Gene Expression Regulation, NeoplasticAdenomaAnimalsAntimetabolites, AntineoplasticCell Line, TumorFemaleFormatesGlycine HydroxymethyltransferaseIntestinal MucosaIntestinal NeoplasmsIntestinesIsoenzymesMaleMammary Glands, AnimalMammary Neoplasms, ExperimentalMammary Tumor Virus, MouseAntimetabolites, AntineoplasticFormatesformic acidGlycine HydroxymethyltransferaseIsoenzymesMethotrexateSerineShmt1 protein, mouse

Identifiers

PMID29636461
PMCPMC5893600
OpenAlexW2796845545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.